APTITUDE HEALTH®

EPICS

Conference Coverage: WCLC 2025 Highlights

September 15, 2025

Report Contents

EPICS

Content	Link
Meeting Snapshot	
Faculty Panel	
Meeting Agenda	
Key Insights and Strategic Recommendations	
EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge	
Oncogenic Drivers and Other Mutations in Advanced NSCLC	
Targeted Therapy in Resectable NSCLC	
Immunotherapy in Resectable NSCLC	
Immunotherapy in Stage III/IV NSCLC	
New Agents and Approaches in SCLC	

Meeting Snapshot: 2025 World Conference on Lung Cancer

EPICS

A closed-door roundtable discussion focused on lung cancer was held virtually on **September 15, 2025**

Lung cancer-specific discussions on latest research updates, therapeutic advances, and their application in clinical decision-making were led by **Corey Langer, MD, FACP,** from the University of Pennsylvania

The panel consisted of 9 key experts in lung cancer

- 2 from Europe
- 6 from US
- 1 from Canada



Insights report includes postmeeting analyses and actionable recommendations

Panel Consisting of 6 US, 1 Canadian, and 2 European Lung Cancer Experts

EPICS

Natasha B. Leighl, MD, FRCPC, FASCO
Princess Margaret Cancer Centre

Marina Chiara Garassino, MD
University of Chicago

Hossein Borghaei, DO
Fox Chase Cancer Center

Federico Cappuzzo, MD, PhD
Regina Elena National Cancer Institute

Helen Ross, MD
Rush Cancer Center

CHAIR:
Corey Langer, MD, FACP
University of Pennsylvania

Sandip Patel, MD
University of California, San Diego

Ignacio Wistuba, MD
Moffitt Cancer Center

Luis Paz-Ares, MD, PhD
Hospital Universitario 12 de Octubre

APTITUDE HEALTH

Meeting Agenda

Time (EDT)	Topic	Speaker/Moderator
10.00 AM – 10.05 AM (5 min)	**Welcome and Introductions**	Corey J. Langer, MD, FACP
10.05 AM – 10.25 AM (20 min)	**EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge**	Federico Cappuzzo, MD, PhD
10.25 AM – 10.50 AM (25 min)	Discussion	All faculty
10.50 AM – 11.05 AM (15 min)	**Oncogenic Drivers and Other Mutations in Advanced NSCLC**	Sandip Patel, MD Hossein Borghaei, DO
11.05 AM – 11.25 AM (20 min)	Discussion	All faculty
11.25 AM – 11.35 AM (10 min)	**Targeted Therapy in Resectable NSCLC**	Helen Ross, MD
11.35 AM – 11.55 AM (20 min)	Discussion	All faculty
11.55 AM – 12.05 PM (10 min)	BREAK	
12.05 PM – 12.15 PM (10 min)	**Immunotherapy in Resectable NSCLC**	Natasha Leighl, MD
12.15 PM – 12.35 PM (20 min)	Discussion	All faculty
12.35 PM – 12.55 PM (20 min)	**Immunotherapy in Stage III/IV NSCLC**	Marina Garassino, MD
12.55 PM – 1.20 PM (25 min)	Discussion	All faculty
1.20 PM – 1.35 PM (15 min)	**New Agents and Approaches in SCLC**	Luis Paz-Ares, MD, PhD
1.35 PM – 1.55 PM (20 min)	Discussion	All faculty
1.55 PM – 2.00 PM (5 min)	**Wrap-Up Comments and Adjourn**	Corey J. Langer, MD, FACP

APTITUDE HEALTH®

EPICS

EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge

Conference Highlights Presented by
Federico Cappuzzo, MD, PhD

Abstract Selection (1/2)

EPICS

Abstract Selection (2/2)

EPICS

First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in *EGFR*m Advanced NSCLC: FLAURA2 Final Overall Survival

Planchard D, et al. WCLC 2025. Abstract PL02.06

EPICS

APTITUDE HEALTH®

First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in *EGFR*m Advanced NSCLC: FLAURA2 Final Overall Survival

Planchard D, et al. WCLC 2025. Abstract PL02.06

EPICS





Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with *EGFR*+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi

Goldman JW, et al. WCLC 2025. Abstract PL02.12

EPICS

APTITUDE HEALTH

Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with *EGFR*+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi

EPICS

Goldman JW, et al. WCLC 2025. Abstract PL02.12





A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With *EGFR* Exon 20 Insertion Mutations

Wang M, et al. WCLC 2025. Abstract MA08.01

EPICS

APTITUDE HEALTH®

A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With *EGFR* Exon 20 Insertion Mutations

Wang M, et al. WCLC 2025. Abstract MA08.01

EPICS



Zipalertinib in NSCLC Patients (Pts) With *EGFR* Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab

Piotrowska Z, et al. WCLC 2025. Abstract MA08.02

EPICS



APTITUDE HEALTH®

Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion *EGFR* Mutations

Udagawa H, et al. WCLC 2025. Abstract MA08.04

EPICS

APTITUDE HEALTH®

PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks Plus Lazertinib in First-Line *EGFR*-Mutated Advanced NSCLC

Scott SC, et al. WCLC 2025. Abstract MA08.05

EPICS



APTITUDE HEALTH®

First-Line Subcutaneous Amivantamab Plus Chemotherapy in *EGFR* Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2

Lim SM, et al. WCLC 2025. Abstract MA08.03

EPICS



APTITUDE HEALTH®

Phase I/II Study of Iza-Bren (BL-B01D1) as Monotherapy in Patients With Locally Advanced or Metastatic *EGFR* Mutated NSCLC

Fang W, et al. WCLC 2025. Abstract OA10.03

EPICS

APTITUDE HEALTH®

Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in *EGFR* Mutated Locally Advanced or Metastatic NSCLC Patients

Zhou F, et al. WCLC 2025. Abstract OA10.04

EPICS

APTITUDE HEALTH®

Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in *EGFR* Mutated Locally Advanced or Metastatic NSCLC Patients

Zhou F, et al. WCLC 2025. Abstract OA10.04

EPICS





APTITUDE HEALTH®

EPICS

EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge

Discussion

EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge (1/4)

EPICS

EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge (2/4)

EPICS

[redacted]

EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge (1 of 3)

EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge (4 of 5)

APTITUDE HEALTH®

EPICS

Oncogenic Drivers and Other Mutations in Advanced NSCLC

Conference Highlights Presented by
Sandip Patel, MD, and Hossein Borghaei, DO

Abstract Selection (1/2)

EPICS

APTITUDE HEALTH®

Abstract Selection (2/2)

EPICS

Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in *KRAS* G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

Negrao MV, et al. WCLC 2025. Abstract OA08.02

EPICS



APTITUDE HEALTH®

Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in *KRAS* G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

Johnson ML, et al. WCLC 2025. Abstract MA02.06

EPICS



Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in *KRAS* G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

Johnson ML, et al. WCLC 2025. Abstract MA02.06

EPICS



Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced *KRAS* G12C NSCLC

Lee CK, et al. WCLC 2025. Abstract OA08.04

EPICS



APTITUDE HEALTH®

Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with *KRAS* G12D Mutation

Lu S, et al. WCLC 2025. Abstract MA02.07

EPICS



APTITUDE HEALTH®

Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with *KRAS* G12D Mutation

EPICS

Lu S, et al. WCLC 2025. Abstract MA02.07

Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic *ROS1*+ NSCLC

Drilon AE, et al. WCLC 2025. Abstract PL02.15



Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic *ROS1*+ NSCLC

Drilon AE, et al. WCLC 2025. Abstract PL02.15

EPICS

APTITUDE HEALTH®

Updated Efficacy and Safety of Taletrectinib in Patients With *ROS1+* Non-Small Cell Lung Cancer: The Global TRUST-II Study

Liu G, et al. WCLC 2025. Abstract MA02.02

EPICS

APTITUDE HEALTH®

Repotrectinib in Patients With *ROS1* Fusion-Positive (*ROS1*+) NSCLC: Long-Term Follow-Up From the Phase 1/2 TRIDENT-1 Trial

Cho BC, et al. WCLC 2025. Abstract MA02.03

EPICS

APTITUDE HEALTH®

BMS-986504 in Patients With Homozygous *MTAP*-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007

Janne P, et al. WCLC 2025. Abstract OA08.01

EPICS



APTITUDE HEALTH®

BMS-986504 in Patients With Homozygous *MTAP*-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007

Janne P, et al. WCLC 2025. Abstract OA08.01

EPICS



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Oncogenic Drivers and Other Mutations in Advanced NSCLC

Discussion

Oncogenic Drivers and Other Mutations in Advanced NSCLC (1/4)

EPICS

Oncogenic Drivers and Other Mutations in Advanced NSCLC (2/4)

EPICS

APTITUDE HEALTH®

Oncogenic Drivers and Other Mutations in Advanced NSCLC (3/4)

EPICS

[redacted]

Oncogenic Drivers and Other Mutations in Advanced NSCLC (4/4)

EPICS

APTITUDE HEALTH®

EPICS

Targeted Therapy in Resectable NSCLC

Conference Highlights Presented by
Helen Ross, MD

Abstract Selection

EPICS

Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable *EGFR*m NSCLC

Blakely C, et al. WCLC 2025. Abstract OA02.02

EPICS

APTITUDE HEALTH®

Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA *EGFR* Mutated NSCLC With High Risk (APPOINT)

Zhang W, et al. WCLC 2025. Abstract MA04.03

EPICS



APTITUDE HEALTH®

Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage *ALK*+ NSCLC

Gerber DE, et al. WCLC 2025. Abstract PL02.18

EPICS

Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB *ALK* + NSCLC

Lee JM, et al. WCLC 2025. Abstract MA04.02

EPICS



Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB *ALK* + NSCLC

Lee JM, et al. WCLC 2025. Abstract MA04.02

EPICS



Expert's Insights

"Should we be using it neoadjuvantly, as we may be doing more and more with EGFR-directed neoadjuvant therapy? The results of this small, single-arm basket trial looking at ALK-positive patients suggested that at least that there's no appreciable downside to doing so."

– Dr Ross

Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC

Becharano G, et al. WCLC 2025. Abstract MA03.02

EPICS

APTITUDE HEALTH®

Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC

Becharano G, et al. WCLC 2025. Abstract MA03.02

EPICS

APTITUDE HEALTH®

EPICS

Targeted Therapy in Resectable NSCLC

Discussion

Targeted Therapy in Resectable NSCLC (1/2)

EPICS



APTITUDE HEALTH®

Targeted Therapy in Resectable NSCLC (2/2)

EPICS

[redacted]

APTITUDE HEALTH®

EPICS

Immunotherapy in Resectable NSCLC

Conference Highlights Presented by
Natasha Leighl, MD

Abstract Selection

EPICS

Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study

Mitsudomi T, et al. WCLC 2025. Abstract OA02.03

EPICS



APTITUDE HEALTH®

Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIA NSCLC Patients (NADIM ADJUVANT): a Randomized, Phase 3 Trial

Provencio M, et al. WCLC 2025. Abstract PL03.10

EPICS



Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study

Wakelee H, et al. WCLC 2025. Abstract MA04.04

EPICS

Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN

Cobo M, et al. WCLC 2025. Abstract MA04.09

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Immunotherapy in Resectable NSCLC

Discussion

Immunotherapy in Resectable NSCLC (1/3)

EPICS



Immunotherapy in Resectable NSCLC (2/3)

EPICS

[redacted]

APTITUDE HEALTH®

Immunotherapy in Resectable NSCLC (3/3)

EPICS

[redacted]

APTITUDE HEALTH®

EPICS

Immunotherapy in Stage III/IV NSCLC

Conference Highlights Presented by
Marina Garassino, MD

Abstract Selection (1/2)

EPICS

Abstract Selection (2/2)

EPICS

APTITUDE HEALTH®

EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC

Varlotto JM, et al. WCLC 2025. Abstract PL03.06

EPICS

EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC

EPICS

Expert's Insights

"We need to be focusing a little bit more in the neoadjuvant sphere, where we actually have a chance to let our immune subsets rev up and be active before we add radiation to the mix."

– Dr Ross

APTITUDE HEALTH®

Preliminary Results of the Phase I LuCa-MERIT-1 Trial: An Advanced NSCLC pt Cohort Treated With BNT116 + Cemiplimab Post CRT

Öven BB, et al. WCLC 2025. Abstract MA01.07

EPICS



Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial

Baramidze A, et al. WCLC 2025. Abstract MA10.09

EPICS

APTITUDE HEALTH®

Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial

Baramidze A, et al. WCLC 2025. Abstract MA10.09

EPICS



ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-Small Cell Lung Cancer

Shi Y, et al. WCLC 2025. Abstract OA05.01

EPICS

APTITUDE HEALTH®

Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor Histology

Xiong A, et al. WCLC 2025. Abstract P1.11.83

EPICS

APTITUDE HEALTH®

Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor Histology

Xiong A, et al. WCLC 2025. Abstract P1.11.83

EPICS

APTITUDE HEALTH®

Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor PD-L1 Expression Level

Wang L, et al. WCLC 2025. Abstract P1.11.65

EPICS



APTITUDE HEALTH®

IMM2510, an Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein for Advanced IO-treated SQ-NSCLC: A Phase I Study

Wang P, et al. WCLC 2025. Abstract P3.12.74

EPICS

APTITUDE HEALTH®

Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study

Wang J, et al. WCLC 2025. Abstract PT2.10.03

EPICS



APTITUDE HEALTH®

Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study

Fang W, et al. ASCO 2025. Abstract 8529

EPICS



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Immunotherapy in Stage III/IV NSCLC

Discussion

Immunotherapy in Stage III/IV NSCLC (1/4)

EPICS



APTITUDE HEALTH®

Immunotherapy in Stage III/IV NSCLC (2/4)

EPICS

[redacted]

APTITUDE HEALTH®

Immunotherapy in Stage III/IV NSCLC (3/4)

EPICS

[redacted]

Immunotherapy in Stage III/IV NSCLC (4/4)

EPICS

[redacted]

APTITUDE HEALTH®

EPICS

New Agents and Approaches in SCLC

Conference Highlights Presented by
Luis Paz-Ares, MD, PhD

Abstract Selection (1/2)

EPICS

Abstract Selection (2/2)

EPICS

APTITUDE HEALTH®

Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A BsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis

EPICS

Heymach JV, et al. WCLC 2025. Abstract OA13.02

APTITUDE HEALTH®

Tifcemalimab Plus Toripalimab and Chemotherapy as a First-Line Therapy in ES-SCLC: A Phase Ib/II Study

Yu Y, et al. WCLC 2025. Abstract MA11.03



Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study

Reck M, et al. WCLC 2025. Abstract MA11.04

EPICS



APTITUDE HEALTH®

Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial

Paulson KG, et al. WCLC 2025. Abstract OA13.01

EPICS

APTITUDE HEALTH®

Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial

Paulson KG, et al. WCLC 2025. Abstract OA13.01

EPICS

APTITUDE HEALTH®

Phase 1 Study of DLL3-Targeted CAR-T Cells Armored With dnTGFBR2 in Small-Cell Lung and Large-Cell Neuroendocrine Cancers

Schoenfeld AJ, et al. WCLC 2025. Abstract MA11.01

EPICS

APTITUDE HEALTH®

Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Study

Ahn MJ, et al. WCLC 2025. Abstract OA06.03

Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Study

Ahn MJ, et al. WCLC 2025. Abstract OA06.03

EPICS

APTITUDE HEALTH®

Safety and Efficacy of QLC5508 in Previously Treated Patients with Small Cell Lung Cancer: Updated Data from a Phase 1 Study

Zhou C, et al. WCLC 2025. Abstract OA06.02

EPICS

APTITUDE HEALTH®

A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC

Wang L, et al. WCLC 2025. Abstract OA06.01

EPICS

APTITUDE HEALTH®

Safety and Efficacy of ABBV-706, a Seizure-related Homolog Protein 6-Targeting Antibody-drug Conjugate, in R/R SCLC

Byers LA, et al. WCLC 2025. Abstract OA06.04

EPICS

APTITUDE HEALTH®

RYZ101 (^{225}Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor-Expressing Extensive-Stage SCLC

Mansfield AS, et al. WCLC 2025. Abstract OA13.03

EPICS

APTITUDE HEALTH®

RYZ101 (^{225}Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor-Expressing Extensive-Stage SCLC

Mansfield AS, et al. WCLC 2025. Abstract OA13.03

EPICS



APTITUDE HEALTH®

EPICS

New Agents and Approaches in SCLC

Discussion

New Agents and Approaches in SCLC (1/4)

EPICS



APTITUDE HEALTH®

New Agents and Approaches in SCLC (2/4)

EPICS

[redacted]

New Agents and Approaches in SCLC (3/4)

EPICS

New Agents and Approaches in SCLC (4/4)

EPICS

[illegible]

APTITUDE HEALTH®

US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

EU Laan van Nieuw Oost-Indië 133 F
2593 BM The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com